The biotechnology sector is currently at a strategic crossroads, marked by disruptive technological advancements and pressing economic challenges. The "patent cliff", representing a potential loss of $400 billion, is pushing companies to innovate rapidly to offset patent losses. Artificial intelligence (AI) plays a crucial role in this transformation, facilitating drug discovery and optimizing research and development (R&D) processes. Recent fundraising and strategic partnerships reflect the growing interest in AI within this sector.